ReviewESC heart failure2021
'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor.
Review in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD
Observational Study to Validate a Family Physician Echocardiography Training Programme
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness.ESC heart failure · 2025Pooled it
- Incident heart failure in patients with screening-detected atrial fibrillation: a post hoc analysis of the STROKESTOP and STROKESTOP II studies.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure.ESC heart failure · 2025Trial
- Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).ESC heart failure · 2023Trial
- Longitudinal Trajectories of Hospitalizations in U.S. Older Adults with Heart Failure.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Increased Heart Failure Risk with Gastric Cancer Progression: A Nationwide Population-Based Cohort Study.Gut and liver · 2026Article
- HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity.Journal of cardiovascular development and disease · 2026Article
- Epigenetic Control of Mammalian Cardiomyocyte Proliferation.Current cardiology reports · 2026Review
- Identifying risk individuals for heart failure diagnosis within two years in the adult population in southern Sweden using gender, age, multimorbidity level, and socioeconomic status.BMC cardiovascular disorders · 2026Article
- Article
- The Association Between Bending Photoplethysmography Waveform Area Index and Congestive Heart Failure.Clinical cardiology · 2026Article
- Plasma Steroids as Biomarkers of Congestion and Predictors of Prognosis in Acute Heart Failure During the Vulnerable Phase.Reviews in cardiovascular medicine · 2026Article
- Vericiguat in the Post-Stabilization Phase of HFrEF: Targeting Residual Risk Across the Ischemia-Decompensation Continuum.International journal of molecular sciences · 2026Review
- Innovative Advances in Non-Invasive Detection Technologies for Heart Failure: Synergistic Application of Multimodal Sensing and Intelligent Algorithms.Reviews in cardiovascular medicine · 2026Review
- ANMCO position paper: ANMCO general assembly 2024-the role of the cardiologist in the management of cardiovascular chronicity.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Endothelial Activation and Stress Index (EASIX) Predicts In-Hospital Mortality in Acute Decompensated Heart Failure with Reduced Ejection Fraction.Diagnostics (Basel, Switzerland) · 2026Article
- Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Integrating remote CIED monitoring into heart failure care: evidence, challenges, and opportunities.Frontiers in cardiovascular medicine · 2026Review
- Constructing a disease management journey map from the acute decompensated heart failure journey perspective: a descriptive qualitative study.International journal of qualitative studies on health and well-being · 2025Article
- Relation Between Neutrophil Count and Left Ventricular Ejection Fraction Following Acute Myocarditis in Adolescents: A Preliminary Study.Children (Basel, Switzerland) · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In heart failure (HF), acute decompensation can occur quickly and unexpectedly because of worsening of chronic HF or to new-onset HF diagnosed for the first time ('de novo'). Patients presenting with acute HF (AHF) have a poor prognosis comparable with those with acute myocardial infarction, and any delay of treatment initiation is associated with worse outcomes. Recent HF guidelines and recommendations have highlighted the importance of a timely diagnosis and immediate treatment for patients presenting with AHF to decrease disease progression and improve prognosis. However, based on the available data, there is still uncertainty regarding the optimal 'time-to-treatment' effect in AHF. Furthermore, the immediate post-worsening HF period plays an important role in clinical outcomes in HF patients after hospitalization and is known as the 'vulnerable phase' characterized by high risk of readmission and early death. Early and intensive treatment for HF patients in the 'vulnerable phase' might be associated with lower rates of early readmission and mortality. Additionally, in the chronic stable HF outpatient, treatments are often delayed or not initiated when symptoms are stable, ignoring the risk for adverse outcomes such as sudden death. Consequently, there is a dire need to better identify HF patients during hospitalization and after discharge and treating them adequately to improve their prognosis. HF is an urgent clinical scenario along all its stages and disease conditions. Therefore, time plays a significant role throughout the entire patient's journey. Therapy should be optimized as soon as possible, because this is beneficial regardless of severity or duration of HF. Time lavished before treatment initiation is recognized as important modifiable risk factor in HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.